Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL4713282

CC(C)[C@H](NS(=O)(=O)CCCc1ccccc1)P(=O)(O)C[C@H](C(=O)O)c1cccc(CN)c1.O=C(O)C(F)(F)F

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CPB2 Q96IY4 1/20 0.39
ANPEP P15144 3/20 0.37
ERAP1 Q9NZ08 2/20 0.37
MMP2 P08253 1/20 0.36
MMP7 P09237 1/20 0.36
MMP9 P14780 1/20 0.36
MMP8 P22894 1/20 0.36
MMP13 P45452 1/20 0.36
MMP14 P50281 1/20 0.36
S1PR4 O95977 6/20 0.35
S1PR1 P21453 6/20 0.35
S1PR5 Q9H228 6/20 0.35
S1PR3 Q99500 4/20 0.35
ADAMTS4 O75173 1/20 0.35
KLKB1 P03952 1/20 0.34
PLG P00747 1/20 0.34
PLAU P00749 1/20 0.34
TPSAB1 Q15661 1/20 0.34
LMNA P02545 1/20 0.33
CNR1 P21554 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6130893 0.95 CPB2 (0.42) CPB2ANPEPERAP1MMP2MMP7
SCHEMBL2351855 0.95 CPB2 (0.42) CPB2ANPEPERAP1MMP2MMP7
SCHEMBL2350989 0.95 CPB2 (0.42) CPB2ANPEPERAP1MMP2MMP7
SCHEMBL2357292 0.95 CPB2 (0.42) CPB2ANPEPERAP1MMP2MMP7
SCHEMBL2356327 0.95 CPB2 (0.42) CPB2ANPEPERAP1MMP2MMP7
SCHEMBL2349012 0.95 CPB2 (0.42) CPB2ANPEPERAP1MMP2MMP7
SCHEMBL2353899 0.92 CPB2 (0.41) CPB2ANPEPERAP1MMP2MMP7
SCHEMBL23752492 0.90 ANPEP (0.41) CPB2ANPEPERAP1MMP2MMP7
SCHEMBL23752491 0.90 ANPEP (0.41) CPB2ANPEPERAP1MMP2MMP7
SCHEMBL2353264 0.90 ANPEP (0.41) CPB2ANPEPERAP1MMP2MMP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1874322-A1 USE OF TAFI INHIBITORS FOR ENHANCED MYOCARDIAL REPERFUSION AND FACILITATED PCI Bayer Schering Pharma Aktiengesellschaft (DE) 2008-01-09 EP disclosed
WO-2006113247-A1 USE OF TAFI INHIBITORS FOR ENHANCED MYOCARDIAL REPERFUSION AND FACILITATED PCI BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2006-10-26 WO disclosed
US-20060234986-A1 Use of TAFI inhibitors for enhanced myocardial reperfusion and facilitated PCI SCHERING AKTIENGESELLSCHAFT (DE) 2006-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060234986-A1 Use of TAFI inhibitors for enhanced myocardial reperfusion and facilitated PCI TFPI, TFPI2, TNNI3 CPB2 78/4885ANPEP 1254/4885ERAP1 739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.